Compare ICFI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | IMCR |
|---|---|---|
| Founded | 1969 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2006 | 2016 |
| Metric | ICFI | IMCR |
|---|---|---|
| Price | $68.89 | $29.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $99.25 | $66.33 |
| AVG Volume (30 Days) | ★ 398.9K | 366.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ 1.12 | 0.25 |
| Revenue | ★ $1,229,162,000.00 | $249,428,000.00 |
| Revenue This Year | $4.12 | $14.57 |
| Revenue Next Year | $5.33 | $8.21 |
| P/E Ratio | ★ $15.02 | $122.22 |
| Revenue Growth | 3.72 | ★ 43.05 |
| 52 Week Low | $64.34 | $27.47 |
| 52 Week High | $101.71 | $40.71 |
| Indicator | ICFI | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 47.99 |
| Support Level | $64.43 | $28.23 |
| Resistance Level | $74.37 | $34.35 |
| Average True Range (ATR) | 3.18 | 1.35 |
| MACD | 0.45 | 0.16 |
| Stochastic Oscillator | 43.73 | 53.87 |
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.